Bristol Myers Squibb (CELG-RI) Interest Expenses (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Interest Expenses of $407.0 million for Q2 2026, down 16.08% year-over-year from $485.0 million in Q2 2025, and down 13.95% quarter-over-quarter from $473.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Interest Expenses (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Interest Expenses for 18 consecutive years, with $407.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses fell 16.08% year-over-year to $407.0 million; the TTM figure through Jun 2026 stood at $1.8 billion (down 16.59% YoY), while the FY2025 annual figure was $2.6 billion, up 31.95% from the prior year.
- Interest Expenses slipped to $407.0 million in Q2 2026 per CELG-RI's latest filing, from $473.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $624.0 million in Q1 2025 and bottomed at $268.0 million in Q4 2023.
- Historically, Interest Expenses has averaged $403.3 million across 5 years, with a median of $403.5 million in 2025.
- Annual changes were most pronounced in 2024 — Interest Expenses soared 85.07% — and 2026, when it slipped 24.2%.
- Bristol Myers Squibb's Interest Expenses stood at $300.0 million in 2022, then dropped by 10.67% to $268.0 million in 2023, then jumped by 85.07% to $496.0 million in 2024, then retreated by 19.35% to $400.0 million in 2025, then advanced by 1.75% to $407.0 million in 2026.
- Business Quant data shows CELG-RI's Interest Expenses at $407.0 million in Q2 2026, $473.0 million in Q1 2026, and $400.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407.00 Mn |
| Jun 30, 2026 | 407.00 Mn |
| Mar 31, 2026 | 473.00 Mn |
| Mar 31, 2026 | 473.00 Mn |
| Dec 31, 2025 | 400.00 Mn |
| Dec 31, 2025 | 400.00 Mn |
| Sep 30, 2025 | 480.00 Mn |
| Sep 30, 2025 | 480.00 Mn |
| Jun 30, 2025 | 485.00 Mn |
| Jun 30, 2025 | 485.00 Mn |
| Mar 31, 2025 | 624.00 Mn |
| Mar 31, 2025 | 624.00 Mn |
| Dec 31, 2024 | 496.00 Mn |
| Dec 31, 2024 | 496.00 Mn |
| Sep 30, 2024 | 505.00 Mn |
| Sep 30, 2024 | 505.00 Mn |
| Jun 30, 2024 | 521.00 Mn |
| Jun 30, 2024 | 521.00 Mn |
| Mar 31, 2024 | 425.00 Mn |
| Mar 31, 2024 | 425.00 Mn |